-
Biogen And Gilead Sciences Buck Biotech Short Interest Trend
Sunday, June 12, 2016 - 2:35pm | 588Read More...Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...
-
5-Star Biotech Stock Watch: Anacor Pharmaceuticals
Wednesday, July 2, 2014 - 11:09am | 434Read More...Sometimes an “up” day isn’t just any “up” day. Not only did the stock market push higher yesterday, the S&P made a very specific, positive move in the form of a break through its 3-year channel resistance. This should lead to an increase in prices for the S&P...
-
Top Double Digit Winners and Losers From Wednesday, August 14, 2013
Thursday, August 15, 2013 - 1:38pm | 674Read More...Sure, Apple (NASDAQ: AAPL) and its move above $500 was big news, but among the small- and medium-cap names, there were newsworthy events along with double digit moves that could have made you a lot of money. Don’t just see these big moves as a one-day event. History shows that often, there is...
-
Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)
Saturday, March 23, 2013 - 11:33am | 835Read More...Some smaller health care companies saw unusual movement in their stocks on Friday. And not just in Anacor Pharmaceuticals (NASDAQ: ANAC), Halozyme Therapeutics (NASDAQ: HALO), Puma Biotechnology (NYSE: PBYI) and Questcor Pharmaceuticals (NASDAQ: QCOR), which are discussed below. But also ACADIA...
-
Deutsche Bank Maintains Buy Rating On ANAC
Thursday, April 7, 2011 - 7:28am | 95Read More...Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) “is an emerging pharmaceutical company developing new drugs based on boron chemistry, an area that has largely been neglected by industry to date,” Deutsche Bank reports. “Anacor has developed expertise in identifying and synthesizing boron-based...
